29681-42-3

Basic information

• Product Name: 4-BROMO-PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER
• Synonyms: METHYL 4-BROMOPICOLINATE;METHYL 4-BROMOPYRIDINE-2-CARBOXYLATE;METHYL 4-BROMO-2-PYRIDINECARBOXYLATE;4-BROMO-PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER;Methyl 4-bromopyridine-2-carboxylate 97%;4-Bromo-2-pyridinecarboxylic acid methyl ester;Methyl 4-broMopyridine-2-...;2-Pyridinecarboxylic acid, 4-broMo-, Methyl ester
• CAS NO: 29681-42-3
• Molecular Formula: C₇H₆BrNO₂
• Molecular Weight: 216.03
• EINECS: -0
• Product Categories: blocks;Bromides;Carboxes;Pyridines
• Mol File: 29681-42-3.mol
• Article Data: 10

Chemical Properties

• Melting Point: 54-56
• Boiling Point: 285.967 °C at 760 mmHg
• Flash Point: 126.749 °C
• Appearance: /Solid
• Density: 1.58 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: Keep Cold
• PKA: -0.25±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 4-BROMO-PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER(29681-42-3)
• EPA Substance Registry System: 4-BROMO-PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER(29681-42-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 29681-42-3(Hazardous Substances Data)

Usage

Chemical Properties

yellow solid

Uses

It finds its application as a useful synthetic intermediate and in the straightforward and efficient synthesis of 3-benzyloxy-4-bromopicolinate ester and 3-benzyloxy-5-bromopicolinate ester, common building blocks for pharmaceuticals and agrochemicals. It is used in the synthesis of biaryl mannoside FimH inhibitors for use in urinary infection treatment.

InChI:InChI=1/C7H6BrNO2/c1-11-7(10)6-4-5(8)2-3-9-6/h2-4H,1H3

Upstream product

• 30766-03-1 4-bromo-2-picolinic acid 
• 74-88-4 methyl iodide 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 600-22-6 pyruvic acid methyl ester 
• 1120-87-2 4-bromopyridin 
• 19524-06-2 4-bromopyridine hydrochloride 
• 186581-53-3 diazomethane 

Downstream Products

• 946000-01-7 trans-methyl 4-(3-{[[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-(3-chloro-4,7-difluoro-benzo[b]thiophene-2-carbonyl)-amino]-methyl}-4-methoxy-phenyl)-pyridine-2-carboxylate 
• 1244016-83-8 methyl 4-(2-phenylethynyl)pyridine-2-carboxylate 
• 1244021-20-2 methyl 4-(2-fluorobiphenyl-4-yl)picolinate 
• 1244018-24-3 methyl 4-{4-[(4-formylphenyl)ethynyl]phenyl}pyridine-2-carboxylate 
• 131747-45-0 4-bromo-2-(hydroxymethyl)pyridine 
• 477252-20-3 2-(4-bromopyridin-2-yl)propan-2-ol 
• 2362010-59-9 4-(dimethylphosphoryl)picolinic acid 
• 312325-73-8 2-(4-bromopyridin-2-yl)acetonitrile 
• 1005342-94-8 4-bromo-pyridine-2-carboxylic acid N-methoxy-N-methyl-amide 
• 30766-03-1 4-bromo-2-picolinic acid 
• 957062-72-5 methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carboxylate 

Relevant articles and documents

CD38 INHIBITORS

One embodiment of the invention is a compound represented by Formula I: or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject.

HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS

The invention relates to chemical compounds of formula (IB): or a salt thereof. In some embodiments, the invention relates to inhibitors of UDP-3-0 — (R-S-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein and their use in the prevention and/or treatment of Gram- negative bacterial infections.